The Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel) and LYFGENIA™ (lovotibeglogene autotemcel), the first two gene therapies for the treatment of sickle cell disease  in patients 12 years and older with recurrent vaso-occlusive crises (VOCs). 

Find out about Mrs. Carter’s impact on vaccines in the U.S. Check out a study on influenza disease and vaccine in kids. And find out about the Polio Network, a national and international resource for individuals and families affected by polio.

Find out about different viruses that cause symptoms similar to influenza and what distinguishes these “common colds” from “the flu.”

Recurrent respiratory papillomatosis (RRP) is a disease characterized by the growth of noncancerous tumors around the vocal cords caused by HPV infection. Find out more about RRP and the work of the Recurrent Respiratory Papillomatosis Foundation.

In 2016, our 8-year-old son Justin was airlifted to CHOP for emergency brain surgery. It hit us out of nowhere. When his sister and brother visited, Child Life came in with things like Legos and Play-Doh to distract them from his scary head wrap and get them to just play together. It took the fear out of the room.

The College of Healthcare Information Management Executives (CHIME) has released their Digital Health Most Wired Survey results for the 2023 data collection period, and Children's Hospital of Philadelphia (CHOP) is excited to announce we have maintained our highest ranking to date: Acute Level 8 achievement for the Digital Health Most Wired range.

Identifying “backbones” that link complexes can help maximize CAR therapy across different variants and tumor types.

Today, Children’s Hospital of Philadelphia’s Center for Violence Prevention (CVP) marks a major milestone -- 10 years of unified programming and research focused on reducing exposure to and impact of violence on youth and their families.

How CHOP is responding to the national RSV medication shortage and keeping your baby safe.

This major step allows for the creation of clinical trials to test key endpoints that will determine the efficacy of new therapies.